Fall Clinical News: Guselkumab Performs Well in Special Areas of Psoriasis
Guselkumab (Tremfya, Johnson & Johnson) results in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis with special site involvement (scalp, face, skin folds and genitals) who had failed topical treatment, according to data from the Phase 3b SPECTREM study presented at 2024 Fall Clinical Dermatology Conference […]